Osteoarthritis (OA) and the non-steroidal anti-inflammatory drugs (NSAIDs) used to relieve OA-associated pain have been linked independently to increased cardiovascular risk. We examined the risk of cardiovascular events associated with NSAID use in patients with OA. We employed linked nationwide administrative registers to examine NSAID use between 1996 and 2015 by Danish patients with OA aged ≥18 years.
Osteoarthritis (OA) is the most common form of joint disease worldwide, 5 as well as a leading cause of chronic pain, disability and reduced quality of life resulting in a considerable burden to society. 6 Still, NSAIDs are the cornerstone for effective pain management of patients with OA. 7 OA and cardiovascular disease share diverse risk factors, such as ageing, obesity and physical inactivity. 8 Moreover, patients with OA have a high prevalence of cardiovascular risk factors such as hypertension, diabetes and hypercholesterolaemia 8 ; hence, they carry an elevated cardiovascular hazard and are potentially more susceptible to cardiovascular adverse effects of NSAIDs than the general population. 9 Non-steroidal anti-inflammatory drugs provide their analgesic, antipyretic and anti-inflammatory effects through the inhibition of the enzyme cyclooxygenase, which catalyses the rate-limiting step in the formation of prostanoids, prostaglandins and thromboxane A2. 9 The harmful cardiovascular effect seems to be shared by all the drugs of this group. 10 Nonetheless, differences in pharmacokinetic and pharmacodynamic characteristics suggest drug-specific cardiovascular profiles. 9 The Food and Drug Administration (FDA)-mandated Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen (PRECISION) trial, undertaken while celecoxib remained on the market, aimed to elucidate the comparative cardiovascular safety of celecoxib, ibuprofen and naproxen in patients with arthritis. 11 The results of PRECISION are challenging to interpret owing to their numerous limitations. 9, [12] [13] [14] Conflicting opinions and debate remain about the cardiovascular profile and safety of celecoxib, ibuprofen and naproxen, especially at different dosages, in OA. This prompted us to examine an unselected cohort of patients with OA where we focused on risk of cardiovascular death, acute myocardial infarction (MI) and ischaemic stroke associated with the use of NSAIDs aiming to demonstrate whether differences existed between the individual drugs and their doses.
| MATERIALS AND METHODS
The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies. 15 
| Data sources
In Denmark, every resident has a permanent and unique civil registration number that permits linkage between administrative registries. All hospital admissions have been recorded since 1978 in the Danish National Patient Registry with one primary diagnosis and one or more secondary diagnoses, encoded according to the International Classification of Diseases (ICD), until 1994 the ICD-8 and from 1994 the ICD-10. The Danish National Prescription Registry has since 1995 registered all prescriptions from pharmacies in Denmark and every drug is classified by the Anatomical Therapeutical Chemical (ATC) system. The Central Person Registry comprises information about vital and migration status. The National Causes of Death Register contains the cause of death registered using the ICD-10 classification system.
| Study population
This nationwide cohort study includes all adult patients, aged ≥18 years with first contact with the Danish health care system (both hospitalization and ambulatory) for OA between 1 January 1996 and 31 December 2015.
We started follow-up 7 days after the discharge or outpatient contact (index date) until one of the following events (whichever came first): emigration, death, outcome of interest (cardiovascular death, non-fatal ischaemic stroke or MI), 5-year follow-up after index date or end of study period (31 December 2015) . Patients were included in the analysis only if they were alive and had not yet experienced the outcomes of interest at the index date.
| Non-steroidal anti-inflammatory drug use
We identified all claimed prescriptions for NSAIDs (ATC M01A, excluding M01AX05 glucosamine) from the Danish National Prescription Registry after the index date. The most commonly used selective cyclooxygenase-(COX) 2 inhibitors, rofecoxib and celecoxib, and the most commonly used non-selective NSAIDs, ibuprofen, diclofenac and naproxen, were analysed separately. All other NSAIDs were analysed in a common group defined as "other NSAIDs" (Table S1 ).
| Dose and duration of treatment
The national prescription registry does not include information on the prescribed daily dosage of medications. Accordingly, the daily dosage was determined at each new dispensed prescription by calculating average dose from up to three consecutive prescriptions prior to the actual one. For each prescription, the number of tablets dispensed was divided by the estimated daily dosage to calculate the treatment duration. This approach also allowed the dose to increase if subsequent prescriptions were filled before tablets were consumed. If tablets were still available for consumption based on the approximation of exposure at the time of a new prescription for the same NSAID, exposure was defined as an uninterrupted treatment episode.
The approximation of drug exposure was based on continuous assessment of new prescriptions during exposure and not on future prescriptions; hence, exposure was not conditioned on future use. If only one prescription was registered for a patient, the daily dosage was estimated as the minimum recommended dosage. Discontinuation of the prescribed NSAID was defined as the point when patients had no more medication available. Patients were allowed to change the NSAID treatment regimen during the study period. Therefore, exposure to NSAIDs was included as a time-dependent variable in the models. The patients were permitted to be in only one drug exposure group at a time but could change groups. If a patient was exposed to more than one NSAID at the same time, we defined a sequence of use (rofecoxib, celecoxib, diclofenac, naproxen, other) to allow all explanatory variables in one model. The baseline NSAID treatment was defined as availability of tablets from 7 days after hospital discharge or outpatient contact for OA to 6 months before. The method we employed has been described in detail in an online document and has been previously applied in other studies from our group. 16, 17 High dose was defined as being above the upper limit of the recommended minimal dose for each drug 18,19 : ibuprofen >1200 mg; diclofenac >100 mg; naproxen >500 mg; rofecoxib >25 mg; and celecoxib >200 mg.
| Comorbidity and concomitant medication
The Ontario acute MI mortality prediction rule modified for the ICD-10 was used to identify comorbidity. 20 Also, we identified discharge diagnoses up to 5 years before the index date. Concomitant use of β-blockers, angiotensin-converting enzyme inhibitors/angiotensin 2 receptor blockers, statins, weak and strong opioids, and antidiabetic drugs, the latter a proxy for prevalence of diabetes, 21 was defined as claimed prescriptions within 180 days before index date. The exposure status to aspirin was continually updated during the follow-up period. We also identified joint replacement surgery (knee or hip alloplasty) and bone fractures during the follow-up period. In fact, patients with OA have an enhanced risk of undergoing alloplasty and fractures, which lead to augmented pain and so augmented use of painkillers. The codes used to identify comorbidity and medication are listed in Table S2 .
| Outcome measures
The primary outcome was a composite of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke/transient ischaemic attack. The three end-points were also analysed separately. The diagnosis of MI in the Danish registries has previously been validated with a positive predictive value of 92% to 100%. 22 Stroke was defined as cerebral infarction, unspecified stroke and transient ischaemic attack: this diagnosis has also been formerly validated with a positive predictive value of 97%. 22 The outcome of cardiovascular death was defined as a combination of coronary death or death caused by thromboembolic events (ischaemic stroke, transient ischaemic attack or arterial embolism) as done previously. 23 Details on ICD codes used to classify the outcomes are listed in the Table S2 .
| Statistical analysis
We calculated crude incidence rates as number of events per 100 person-years for the composite outcome of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke according to NSAID treatment. We estimated the effects of the different NSAIDs on the outcomes using adjusted Cox regression models in terms of hazard ratios (HRs) and 95% confidence intervals. Exposure to NSAIDs was included as a time-dependent variable in the models, ensuring that patients were only considered at risk when exposed to the respective drug. Each patient could have multiple independent treatment courses with the same drug but also with different drugs. Hence, current NSAID use was specifically compared with non-current NSAID use in our main analyses. Similarly, in additional analyses, we used ibuprofen and celecoxib, overall and at low dose, as reference.
Finally, we performed a series of additional sub-analyses in which (a) we stratified by the localization of OA (knee, hip or spine); we included only individuals (b) with and without previous cardiovascular disease, that is, patients with and without MI, ischaemic heart disease, stroke or PAD, respectively; (c) new users of NSAIDs (defined as not exposed to NSAIDs during the 6 months before the index date); and (d) who underwent joint replacement surgery during follow-up. All models were adjusted for age, sex, concomitant medication and comorbidity as listed in Table 1 . Bone fractures and aspirin use were included as a time-dependent variable.
We also determined how the use of these drugs changed during the study period by calculating the number of patients who were in treatment with the various NSAIDs as percentage of the total included population.
Lastly, we performed Schneeweiss analyses 24 to assess how strong an unmeasured confounder, unbalanced distributed between the two compared groups, should be to fully explain the observed findings. We used Stata statistical package, version 14 (Stata Corp LP, College Station, TX, USA), for the Cox proportional hazards analysis with time-dependent variables and incidence rates. The rest of the statistical analyses and data BARCELLA ET AL. We also computed daily dosages for chronic users (>90 days) since the accuracy of our estimates becomes better with continued use: the estimates were similar (Table S3) . Moreover, we calculated the average daily dosage and average treatment duration in patients receiving low and high dosage, respectively: we observed that the doses were comparable-for all the drugs they fell just under the threshold that we chose for definition of the category; notably, naproxen at low dosage was prescribed for a longer period compared to the other NSAIDs (Table S3 ).
| NSAID use over time
Regarding the use of NSAID during the study period (Figure 1 
| Main analyses
In the adjusted model, the overall NSAID use was associated with increased hazard ratio (HR) of 1.31 (95% confidence interval [CI]: 1.27-1.35), compared to no NSAID treatment ( Figure 2 ). When studied individually, all the examined NSAIDs were associated with elevated risk of the composite outcome compared to no NSAID use. Similar results were seen when fatal and non-fatal ischaemic stroke and MI and cardiovascular death were analysed separately ( Figure 2 ). In the dose-related analyses, a dose-dependent increase in risk was seen for the composite outcome with the individual NSAIDs ( Figure 3 ). Low dose of the non-selective NSAIDs, naproxen and ibuprofen, was associated with the lowest risks regarding the composite outcome (HRs: 1.12 [1.07-1.19] and 1.16 [0.92, 1.42], respectively), compared to no NSAID treatment (Figure 3) . When MI and stroke were examined separately ( Figure S1A,B) , we obtained comparable results. Low dosages of naproxen and ibuprofen were not significantly associated with increased risk of cardiovascular death ( Figure S1C ) compared to no NSAID treatment.
| Additional analyses

| Ibuprofen as reference
When compared to ibuprofen (Figure 4) , only naproxen showed a similar cardiovascular risk profile: rofecoxib, celecoxib (not for stroke) and diclofenac were associated with greater cardiovascular risk. When low-dose ibuprofen (≤1200 mg) was used as comparator ( Figure S2 ), rofecoxib, celecoxib and diclofenac had greater HRs for the composite outcome at low and high dosages; conversely, naproxen at any dose seemed to have neutral effects.
| Celecoxib as reference
When we performed analyses using celecoxib as reference ( Figure 5 ), exposure to naproxen and ibuprofen was associated with a significantly lower risk of all cardiovascular outcomes except for stroke. Similarly, we observed increased HRs for the composite outcome for users of lowdose celecoxib (<200 mg) as compared with low-dose ibuprofen and naproxen ( Figure S3 ).
| Sub-analyses
Repeating the analyses for the composite outcome stratifying for the localization of OA (knee, hip or spine) did not affect the results ( Figure S4 ) as well as when we examined separately patients with and without previous cardiovascular disease, respectively ( Figures S5 and S6) . We found new users of NSAIDs to be associated with a significantly higher cardiovascular risk of the composite outcome compared to main analysis including both new and prevalent users ( Figure S7 ). Nevertheless, also among new users, celecoxib had an enhanced cardiovascular hazard compared to ibuprofen and naproxen ( Figure S7B,C) . The results of the Schneeweiss analysis indicated that the presence of an unmeasured confounder, or a combination of confounders, unbalanced distributed in the two compared groups by a 17% factor (the overall incidence of obesity in Denmark), had to increase the risk (a) by a factor of 3.0-3.5 in the comparison between NSAID users and non-NSAID users and (b) by a factor of 2.0-2.5 in the comparison between celecoxib users and ibuprofen users to explain the increased risk observed (Figures S8 and S9 ).
| Patients who underwent joint replacement surgery
During the follow-up period, 105 606 patients (19.8%) underwent joint replacement surgery, 80 483 of whom were in the NSAID group. When we evaluated HRs for the composite outcome in the perioperative period, exposure to any NSAIDs was related to an elevated risk in the adjusted models compared with no treatment: HR: 1.11 (1.04-1.18). Examining the different NSAIDs individually, the composite outcome increased significantly by rofecoxib 1.44 (1.13-1.83) and diclofenac 1.20 (1.04-1.38) and non-significantly by celecoxib and naproxen, but not by ibuprofen 1.00 (0.91-1.10; Figure S10 ).
| DISCUSSION
In this nationwide study of patients with OA, we found significant differences in the cardiovascular profile of individual NSAIDs. All the currently available widely prescribed NSAIDs (ibuprofen, naproxen, diclofenac and celecoxib) were associated with elevated cardiovascular risk. Low-dose naproxen and ibuprofen seemed to be associated with the lowest cardiovascular risk. Compared with these two non-selective NSAIDs, celecoxib showed increased cardiovascular risk, even at a low dose. Our F I G U R E 2 Risk of all outcomes with usage of specific NSAIDs compared with no NSAID treatment. Crude incidence rate and unadjusted and adjusted Cox proportional hazard ratio of composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference group: no treatment with NSAIDs. NSAID, nonsteroidal anti-inflammatory drugs. *per 100 person-years results differ from those of two recent RCTs, PRECISION and SCOT, which found celecoxib to be non-inferior to ibuprofen or naproxen regarding cardiovascular safety.
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| Pharmacokinetic and pharmacodynamic characteristics
Despite their shared analgesic and anti-inflammatory effects and common mechanisms of action, NSAIDs differ in pharmacokinetic and pharmacodynamic properties; therefore, small but clinically important differences exist in their cardiovascular profile. 26 Celecoxib is a selective COX-2 inhibitor, with less potency but longer half-life compared to diclofenac. 9 Ibuprofen and naproxen inhibit both COX-isoforms: while ibuprofen has a short half-life (about 2-3 hours) and hence yields only a transient and reversible block of the COX-1-mediated production of thromboxane A2, naproxen has a particularly long half-life which permits a sustained suppression of platelet COX-1 activity potentially mimicking the effects of aspirin if dosed on a sustained basis. 9, 27 However, the potential cardioprotective effect of naproxen is difficult to attain outside of a strictly regulated randomized trial, and moreover, its pharmacokinetics is characterized by strong interindividual heterogeneity.
| Results in the context of PRECISION
Several characteristics may explain the divergent results between PRECISION and our study. Firstly, different dosages of the three NSAIDs were compared: in PRECI-SION, the mean daily dose of celecoxib fell into the low dosage group, while in the medium high for ibuprofen and naproxen. 11, 19 The imbalance was particularly noticeable in patients with OA, since ibuprofen and naproxen dose could F I G U R E 3 Risk of composite outcomes with usage of different NSAID doses compared with no NSAID treatment. Crude incidence rate and unadjusted and adjusted Cox proportional hazard ratio of composite outcome associated with use of NSAIDs in patients with osteoarthritis in accordance with dose of the drugs. Reference group: no treatment with NSAIDs. NSAID, non-steroidal anti-inflammatory drugs. *per 100 person-years be increased to provide sufficient pain relief, while the daily dosage of celecoxib was capped at 200 mg/d due to regulatory restrictions on a per-country basis. 9, 13 The effects of NSAIDs, both on pain relief and on the cardiovascular system, are closely dose-dependent. 9 In PRECI-SION, the pain control was worse in the celecoxib group compared with the other two drugs: higher rates of drug discontinuation due to "insufficient clinical response" and less anti-arthritic efficacy. 11 Accordingly, ibuprofen and naproxen were more frequently associated with renal events and hospitalization for hypertension. 11 Since the thrombogenic effect of NSAIDs is related to the degree of COX-2 inhibition, which increases with dose, it is not surprising that PRECISION found celecoxib non-inferior in terms of adverse cardiovascular events compared to the two non-selective NSAIDs. Analysing equipotent doses, we observed that celecoxib, even at low dosages (≤200 mg), had significantly increased hazard for the composite outcome compared to low doses of naproxen (≤500 mg) and ibuprofen (≤1200 mg). Our calculation of the ingested daily dose relied on an algorithm based on pre-defined typical dosages and prior prescription patterns; it assumed that all reimbursed NSAIDs were taken regularly and at a fixed mean daily dosage between prescriptions, which does not always happen in reality. We found an average overall daily dosage which fell in the medium dose category for all three drugs. 19 Concurrently, celecoxib and naproxen had an average duration treatment of about 38 days and ibuprofen of 32 days. Also, we observed that the largest part of patients took these medications only for short periods of 1-2 weeks, while the mean duration of treatment in PRECISION in all arms was around 20 months. Therefore, we believe that our calculations reflect more precisely the clinical practice, where NSAIDs are taken intermittently, for short periods, at low or varying dose, and where switch between the various drugs often occur.
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Risk of all outcomes with usage of specific NSAIDs compared with ibuprofen. Crude incidence rate and unadjusted and adjusted Cox proportional hazard ratio of composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference group: patients taking ibuprofen. NSAID, nonsteroidal anti-inflammatory drugs. *per 100 person-years Secondly, we studied a Danish cohort of patients with OA, while PRECISION was conducted primarily in the United States (>80% individuals) plus 13 different nonEuropean countries. Thirdly, our composite outcome included non-fatal MI, stroke and cardiovascular death and hence was narrower compared to the Antiplatelet Trialists Collaboration (APTC) outcome. Fourthly, the two studies had deeply different designs and related limitations. In our registries, we do not have information about important clinical features (blood pressure, smoking habits, left ventricular ejection fraction); therefore, the effect of unmeasured confounders cannot be completely ruled out. To account for selection differences among diverse NSAIDs, we performed sub-analyses including only patients with previous cardiovascular diseases, which confirmed the main results. Moreover, our Schneeweiss analyses demonstrated that an unmeasured confounder must be particularly strong to fully explain our results and the existence of such a confounder, when possible, is highly unlikely. However, selective COX-2 drugs, because of their relative gastrointestinal safety, in clinical practice tend to be channelled towards patients with diverse comorbidities, 30 as testified by the imbalance in cardiovascular diseases between patients taking COX-2 selective drugs and non-selective NSAIDs at baseline. Therefore, despite the robustness of our results, the adjustments for comorbidities and the several sub-analyses, selection bias and residual confounding may have influenced our findings. The average relative risk of cardiovascular complications associated with NSAIDs is in the order of 1.0-2.0. Particularly, a large meta-analysis and a systematic review of observational studies found an increased risk of major vascular events for celecoxib at any dose of 1.36 (95% CI: 1.00-1.84) and at low dose (≤200 mg/d) of 1.16 (95% CI: 1.09-1.47) compared to non-NSAID use, respectively. 18, 31 Therefore, although PRECISION included 24 000 arthritis F I G U R E 5 Risk of all outcomes with usage of specific NSAIDs compared with celecoxib. Crude incidence rate and unadjusted and adjusted Cox proportional hazard ratio of composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference group: patients taking celecoxib. NSAID, non-steroidal antiinflammatory drugs. *per 100 person-years patients, it could not be powered enough to detect slight disparities in the cardiovascular profile of the three examined NSAIDs. 12 celecoxib with non-selective NSAIDs and did not find differences in cardiovascular risk between the two groups. However, in this study, all the non-selective NSAIDs were grouped together, including diclofenac, which is characterized by a degree of COX-2 selectivity and a cardiovascular hazard comparable with COX-2 inhibitors 34 and hence may have diluted the result towards non-inferiority of celecoxib. Notably, in our analyses, diclofenac exhibited a magnitude of risk in accordance with previous studies 35 and a cardiovascular risk profile similar to celecoxib. Moreover, patients taking celecoxib had a higher drop-out rate than those in the non-selective NSAID group, often for a lack of efficacy in pain management. 14 Finally, the on-treatment analysis failed to prove non-inferiority of celecoxib. 9 The results of our study are strengthened by their concordance with the mechanism by which NSAIDs are supposed to confer cardiovascular hazard 9, 22, 26 and with the conclusions of previous large meta-analyses.
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| Limitations
With the observational nature of our study, any conclusion must be drawn with caution. The initial symptoms of ischaemic heart disease could be interpreted as musculoskeletal disorder and thereafter progress to myocardial infarction. Although NSAIDs are not recommended for the treatment of coronary heart disease, we cannot completely exclude the possibility that this will happen. Consequently, it is possible that our results overestimate the NSAID-associated risk. However, the association of NSAIDs with cardiovascular hazard is widely reported. [2] [3] [4] 35 We studied an OA cohort, which minimized the risk of confounding by indication. Moreover, at baseline, the individuals not taking NSAIDs had an overall higher cardiovascular risk (older age and more comorbidities). It is therefore unlikely that confounding-byindication alone would drive our results. In Denmark, from October 2001, ibuprofen, as the only NSAIDs, was available as over-the-counter medicine, but at low dosage (200 mg) and small amounts (maximum 100 tablets). However, in the light of the reimbursement obtainable with a prescription, patients requiring higher doses or long-term treatment, such as patients with OA, would have a financial incentive to obtain prescriptions from their physician. Moreover, restricting the analyses to 1996-2000 did not alter the association between NSAIDs and cardiovascular risk.
| CONCLUSIONS
This nationwide study of an OA cohort suggests that the use of individual NSAIDs was associated with different levels of cardiovascular risk. As NSAIDs are often used in OA, these differences could have considerable impact on OA patients' disease burden. NSAIDs with stronger COX-1 selective profiles, such as naproxen and ibuprofen, at the lowest effective doses, may be preferred for cardiovascular safety.
